A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis

Abstract

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of oncological conditions, including chronic myeloid leukemia and gastrointestinal stromal tumors. The most frequent dermatological side effect reported is pigmentary abnormalities. We report a case series of three Asian Chinese females with preexisting acquired dermal melanocytosis that progressed after initiation of imatinib treatment, and concurrently developed generalized hypopigmentation of the skin. All three patients had similar histological findings on skin biopsy. It is postulated that the KIT/SCF pathway has a central role in the pathogenetic mechanism. Therefore, it is important for physicians to be aware of this potential side effect of paradoxical pigmentation in patients treated with imatinib.

Keywords:

• Imatinib
• hypopigmentation
• dermal melanocytosis
• Hori’s nevus

Acknowledgements

The authors would like to acknowledge the following individuals for their contributions in providing their clinical input in the management of the three cases reported.

Dr. Poh Cheong Roland CHU, National Skin Centre, Singapore

Dr. Tien Guan Steven THNG, National Skin Centre, Singapore

Dr. Wai-Meng David TAI, National Skin Centre, Singapore

All authors were involved in the process of drafting the manuscript.

Disclosure statement

The authors declare no conflicts of interests, including financial support.